Revolution Medicines, Inc. (RVMD) Tops Q3 EPS by 200c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of $0.99, $2.00 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $0 versus the consensus estimate of $750 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Revolution Medicines R&D chief to step down ahead of 2027 retirement
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins